B&K Corporation Limited (HKG:2396)

Market Cap	376.50M
Revenue (ttm)	602.64K +100.0%
Net Income	-281.94M
EPS	-2.58
Shares Out	117.66M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	2,600
Open	3.270
Previous Close	3.270
Day's Range	3.200 - 3.270
52-Week Range	3.100 - 37.200
Beta	n/a
Analysts	n/a
Price Target	n/a
Est. Earnings	Nov 13, 2026

About B&K Corporation

B&K Corporation Limited operates as a biopharmaceutical company developing therapies with an emphasis on protein drugs for indications with medical needs and market opportunities in China. The company primarily focuses on the discovery, development, and commercialization of therapies for wound healing, currently platelet-derived growth factor (“PDGF”) drugs. The company’s pipeline comprised two Core Products including Pro-101-1 for the treatment of deep second-degree thermal burns, which has completed the statistical data analysis for Phase IIb...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2012
• Employees: 103
• Stock Exchange: Hong Kong Stock Exchange
• Ticker Symbol: 2396

Financial Performance

In 2025, B&K Corporation's revenue was 522,000, an increase of 100.00% compared to the previous year's 261,000. Losses were -208.98 million, -1.54% less than in 2024.

Financial numbers in CNY

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Nov 3, 2026

Data Sources Report a data error